Triglycerides as a Shared Risk Factor between Dementia and Atherosclerotic Cardiovascular Disease: A Study of 125 727 Individuals.

BACKGROUND Risk factors for atherosclerotic cardiovascular disease such as smoking, hypertension, physical inactivity, and diabetes have also been associated with risk of dementia. Whether hypertriglyceridemia represents a shared risk factor as well remains unknown. We tested the hypothesis that hypertriglyceridemia is associated with increased risk of non-Alzheimer dementia, Alzheimer disease, and ischemic stroke. METHODS Using the Copenhagen General Population Study and the Copenhagen City Heart Study, we examined the association between increased plasma triglycerides and risk of non-Alzheimer dementia, Alzheimer disease, and ischemic stroke with Cox regression. RESULTS On a continuous scale, higher concentrations of plasma triglycerides were associated with increased risk of non-Alzheimer dementia and ischemic stroke, but not with Alzheimer disease. In age, sex, and cohort adjusted models, the highest percentile of triglycerides (median 629 mg/dL; 7.1 mmol/L) versus the 1-50th percentiles (median 89 mg/dL; 1.0 mmol/L) was associated with hazard ratios of 1.75 (95% confidence interval: 1.17-2.63) for non-Alzheimer dementia, 1.18 (0.73-1.91) for Alzheimer disease, and of 1.89 (1.50-2.38) for ischemic stroke. Corresponding hazard ratios were 1.62 (1.08-2.44), 1.25 (0.77-2.02), and 1.57 (1.24-1.98) in models adjusted multifactorially, and 1.79 (1.16-2.87), 1.18 (0.73-1.92), and 1.46 (1.10-1.95) in models adjusted multifactorially and additionally for apolipoprotein E (APOE) genotype, respectively. Results were similar after excluding individuals who had an event within 2 years after study entry. CONCLUSIONS Moderate hypertriglyceridemia was associated with increased risk of both non-Alzheimer dementia and ischemic stroke, highlighting plasma triglycerides as a shared risk factor between dementia and atherosclerotic cardiovascular disease.

[1]  B. Nordestgaard,et al.  Impact of cardiovascular risk factors and genetics on 10-year absolute risk of dementia: risk charts for targeted prevention , 2020, European heart journal.

[2]  Naaheed Mukadam,et al.  Dementia prevention, intervention, and care: 2020 report of the Lancet Commission , 2020, The Lancet.

[3]  R. Giugliano,et al.  Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. , 2019, Circulation.

[4]  B. Nordestgaard,et al.  High lipoprotein(a) and high risk of mortality. , 2019, European heart journal.

[5]  M. Sabatine,et al.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.

[6]  B. Nordestgaard,et al.  Plasma levels of apolipoprotein E, APOE genotype, and all-cause and cause-specific mortality in 105 949 individuals from a white general population cohort , 2019, European heart journal.

[7]  Deepak L. Bhatt,et al.  Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia , 2019, The New England journal of medicine.

[8]  D. Llewellyn,et al.  Which Risk Factors Causally Influence Dementia? A Systematic Review of Mendelian Randomization Studies , 2018, Journal of Alzheimer's disease : JAD.

[9]  B. Nordestgaard,et al.  Chylomicronemia risk factors ranked by importance for the individual and community in 108 711 women and men , 2018, Journal of internal medicine.

[10]  P. Barber,et al.  Dementia risk and prevention by targeting modifiable vascular risk factors , 2018, Journal of neurochemistry.

[11]  B. Nordestgaard,et al.  Remnant Cholesterol and Myocardial Infarction in Normal Weight, Overweight, and Obese Individuals from the Copenhagen General Population Study. , 2018, Clinical chemistry.

[12]  Tanya M. Teslovich,et al.  Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease , 2017, The New England journal of medicine.

[13]  B. Winblad,et al.  The worldwide costs of dementia 2015 and comparisons with 2010 , 2017, Alzheimer's & Dementia.

[14]  K. Anstey,et al.  Updating the Evidence on the Association between Serum Cholesterol and Risk of Late-Life Dementia: Review and Meta-Analysis , 2016, Journal of Alzheimer's disease : JAD.

[15]  Børge G Nordestgaard,et al.  Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis. , 2016, JAMA internal medicine.

[16]  R. Frikke-Schmidt,et al.  Relation between plasma and brain lipids , 2016, Current opinion in lipidology.

[17]  Dermot F. Reilly,et al.  Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease , 2018 .

[18]  Alun D. Hughes,et al.  Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase , 2016, Journal of the American College of Cardiology.

[19]  Alexander E. Lopez,et al.  Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease. , 2016, The New England journal of medicine.

[20]  B. Nordestgaard Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. , 2016, Circulation research.

[21]  B. Nordestgaard,et al.  Loss-of-function mutation in ABCA1 and risk of Alzheimer's disease and cerebrovascular disease , 2015, Alzheimer's & Dementia.

[22]  Lars Bäckman,et al.  A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial , 2015, The Lancet.

[23]  Anne Tybjærg-Hansen,et al.  Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Blood Pressure as Mediators From Obesity to Ischemic Heart Disease , 2015, Circulation research.

[24]  Alan D. Lopez,et al.  Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2014, The Lancet.

[25]  Anette Varbo,et al.  Triglycerides and cardiovascular disease , 2014, The Lancet.

[26]  Kristine Yaffe,et al.  Potential for primary prevention of Alzheimer's disease: an analysis of population-based data , 2014, The Lancet Neurology.

[27]  B. Nordestgaard,et al.  Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. , 2014, The New England journal of medicine.

[28]  Tanya M. Teslovich,et al.  Common variants associated with plasma triglycerides and risk for coronary artery disease , 2013, Nature Genetics.

[29]  B. Nordestgaard,et al.  Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation , 2013, Circulation.

[30]  B. Nordestgaard,et al.  Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. , 2013, European heart journal.

[31]  B. Nordestgaard,et al.  Remnant cholesterol as a causal risk factor for ischemic heart disease. , 2013, Journal of the American College of Cardiology.

[32]  B. Nordestgaard,et al.  Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population , 2011, Annals of neurology.

[33]  Statins for the treatment of dementia , 2010, Alzheimer's & Dementia.

[34]  J. Danesh,et al.  Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies , 2010, The Lancet.

[35]  J. C. de la Torre Vascular risk factor detection and control may prevent Alzheimer's disease. , 2010, Ageing research reviews.

[36]  P. Amarenco,et al.  Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention , 2009, The Lancet Neurology.

[37]  A. James,et al.  The incorporation and metabolism of amyloid-beta into chylomicron-like lipid emulsions. , 2003, Journal of Alzheimer's disease : JAD.

[38]  J. C. Torre,et al.  Vascular Basis of Alzheimer's Pathogenesis , 2002 .

[39]  AndrewJ. S. Coats MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[40]  R. Collins,et al.  Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. , 1999, American journal of epidemiology.

[41]  M W Knuiman,et al.  Adjustment for regression dilution in epidemiological regression analyses. , 1998, Annals of epidemiology.

[42]  R. Wootton,et al.  Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[43]  R. Wootton,et al.  Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.